245 related articles for article (PubMed ID: 27830513)
1. Condition-specific or generic preference-based measures in oncology? A comparison of the EORTC-8D and the EQ-5D-3L.
Lorgelly PK; Doble B; Rowen D; Brazier J;
Qual Life Res; 2017 May; 26(5):1163-1176. PubMed ID: 27830513
[TBL] [Abstract][Full Text] [Related]
2. Comparison of generic, condition-specific, and mapped health state utility values for multiple myeloma cancer.
Rowen D; Young T; Brazier J; Gaugris S
Value Health; 2012 Dec; 15(8):1059-68. PubMed ID: 23244808
[TBL] [Abstract][Full Text] [Related]
3. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms.
Doble B; Lorgelly P
Qual Life Res; 2016 Apr; 25(4):891-911. PubMed ID: 26391884
[TBL] [Abstract][Full Text] [Related]
4. Which Questionnaire Should Be Used to Measure Quality-of-Life Utilities in Patients with Acute Leukemia? An Evaluation of the Validity and Interpretability of the EQ-5D-5L and Preference-Based Questionnaires Derived from the EORTC QLQ-C30.
van Dongen-Leunis A; Redekop WK; Uyl-de Groot CA
Value Health; 2016; 19(6):834-843. PubMed ID: 27712712
[TBL] [Abstract][Full Text] [Related]
5. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients.
Khan I; Morris S; Pashayan N; Matata B; Bashir Z; Maguirre J
Health Qual Life Outcomes; 2016 Apr; 14():60. PubMed ID: 27072351
[TBL] [Abstract][Full Text] [Related]
6. A comparison of health state utility values associated with oral potentially malignant disorders and oral cancer in Sri Lanka assessed using the EQ-5D-3 L and the EORTC-8D.
Kularatna S; Whitty JA; Johnson NW; Jayasinghe R; Scuffham PA
Health Qual Life Outcomes; 2016 Jul; 14():101. PubMed ID: 27402015
[TBL] [Abstract][Full Text] [Related]
7. Mapping the EORTC QLQ-C30 to EQ-5D-3L in patients with breast cancer.
Gray LA; Hernandez Alava M; Wailoo AJ
BMC Cancer; 2021 Nov; 21(1):1237. PubMed ID: 34794404
[TBL] [Abstract][Full Text] [Related]
8. Responsiveness and convergent validity of QLU-C10D and EQ-5D-3L in assessing short-term quality of life following esophagectomy.
Bulamu NB; Vissapragada R; Chen G; Ratcliffe J; Mudge LA; Smithers BM; Isenring EA; Smith L; Jamieson GG; Watson DI;
Health Qual Life Outcomes; 2021 Oct; 19(1):233. PubMed ID: 34600554
[TBL] [Abstract][Full Text] [Related]
9. Mapping the EORTC-QLQ-C30 to the EQ-5D-3L: An Assessment of Existing and Newly Developed Algorithms.
Woodcock F; Doble B;
Med Decis Making; 2018 Nov; 38(8):954-967. PubMed ID: 30226101
[TBL] [Abstract][Full Text] [Related]
10. Psychometric performance of the CFQ-R-8D compared to the EQ-5D-3L and SF-6D in people with cystic fibrosis.
Mukuria C; Rowen D; Acaster S; McGarry LJ; Lou Y; Sosnay PR; Quittner AL
J Patient Rep Outcomes; 2024 Feb; 8(1):24. PubMed ID: 38416239
[TBL] [Abstract][Full Text] [Related]
11. Study protocol for valuing EQ-5D-3L and EORTC-8D health states in a representative population sample in Sri Lanka.
Kularatna S; Whitty JA; Johnson NW; Scuffham PA
Health Qual Life Outcomes; 2013 Sep; 11():149. PubMed ID: 24070162
[TBL] [Abstract][Full Text] [Related]
12. Mapping EORTC-QLQ-C30 to EQ-5D-3L in patients with colorectal cancer.
Marriott ER; van Hazel G; Gibbs P; Hatswell AJ
J Med Econ; 2017 Feb; 20(2):193-199. PubMed ID: 27676291
[TBL] [Abstract][Full Text] [Related]
13. Testing the validity and responsiveness of a new cancer-specific health utility measure (FACT-8D) in relapsed/refractory mantle cell lymphoma, and comparison to EQ-5D-5L.
Herdman M; Kerr C; Pavesi M; Garside J; Lloyd A; Cubi-Molla P; Devlin N
J Patient Rep Outcomes; 2020 Mar; 4(1):22. PubMed ID: 32219576
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model.
Franken MD; de Hond A; Degeling K; Punt CJA; Koopman M; Uyl-de Groot CA; Versteegh MM; van Oijen MGH
Health Qual Life Outcomes; 2020 Jul; 18(1):240. PubMed ID: 32690011
[TBL] [Abstract][Full Text] [Related]
15. Comparison of contemporaneous responses for EQ-5D-3L and Minnesota Living with Heart Failure; a case for disease specific multiattribute utility instrument in cardiovascular conditions.
Kularatna S; Byrnes J; Chan YK; Carrington MJ; Stewart S; Scuffham PA
Int J Cardiol; 2017 Jan; 227():172-176. PubMed ID: 27865116
[TBL] [Abstract][Full Text] [Related]
16. Choice Defines QALYs: A US Valuation of the EQ-5D-5L.
Craig BM; Rand K
Med Care; 2018 Jun; 56(6):529-536. PubMed ID: 29668646
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Generic and Condition-Specific Preference-Based Measures Using Data From Nivolumab Trials: EQ-5D-3L, Mapping to the EQ-5D-5L, and European Organisation for Research and Treatment of Cancer Quality of Life Utility Measure-Core 10 Dimensions.
Shaw JW; Bennett B; Trigg A; DeRosa M; Taylor F; Kiff C; Ntais D; Noon K; King MT; Cocks K
Value Health; 2021 Nov; 24(11):1651-1659. PubMed ID: 34711366
[TBL] [Abstract][Full Text] [Related]
18. Validity and reliability of the EQ-5D-3L (a generic preference-based instrument used for calculating quality-adjusted life -years) for patients with type 2 diabetes in Iran.
Zare F; Ameri H; Madadizadeh F; Aghaei MR
Diabetes Metab Syndr; 2021; 15(1):319-324. PubMed ID: 33486224
[TBL] [Abstract][Full Text] [Related]
19. VALIDATION AND COMPARISON OF EQ-5D-3L AND SF-6D INSTRUMENTS IN A SPANISH PARKINSON´S DISEASE POPULATION SAMPLE.
Garcia-Gordillo MÁ; Del Pozo-Cruz B; Adsuar JC; Cordero-Ferrera JM; Abellan-Perpiñan JM; Sanchez-Martinez FI
Nutr Hosp; 2015 Dec; 32(6):2808-21. PubMed ID: 26667738
[TBL] [Abstract][Full Text] [Related]
20. A comparison of the EQ-5D-3L and ICECAP-O in an older post-acute patient population relative to the general population.
Couzner L; Crotty M; Norman R; Ratcliffe J
Appl Health Econ Health Policy; 2013 Aug; 11(4):415-25. PubMed ID: 23807538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
